Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

FDA says nay to MDMA, papers retracted

by Sarah Braner
August 15, 2024 | A version of this story appeared in Volume 102, Issue 25

 

The US Food and Drug Administration has rejected Lykos Therapeutics’ application to use methylenedioxymethamphetamine (MDMA) as a treatment for post-traumatic stress disorder. The agency has requested that Lykos conduct another Phase 3 trial. Three papers testing the therapy in the journal Psychopharmacology have been retracted because of concerns about data integrity. The journal says some researchers associated with the Multidisciplinary Association for Psychedelic Studies did not “fully declare a potential competing interest.” Stat News reported than an independent think tank raised concerns over whether severe adverse events were fully described in the data. Finally, the journal cites a specific site where “unethical conduct” took place. Stat News says a trial participant reported that an unlicensed therapist sexually assaulted them. Lykos says the research in the retracted papers wasn’t included in their FDA application.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.